Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: DKK1

Gene summary for DKK1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

DKK1

Gene ID

22943

Gene namedickkopf WNT signaling pathway inhibitor 1
Gene AliasDKK-1
Cytomap10q21.1
Gene Typeprotein-coding
GO ID

GO:0000122

UniProtAcc

I1W660


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
22943DKK1LZE24THumanEsophagusESCC4.23e-04-3.35e-010.0596
22943DKK1P10T-EHumanEsophagusESCC5.34e-06-3.08e-010.116
22943DKK1P16T-EHumanEsophagusESCC1.52e-109.05e-010.1153
22943DKK1P26T-EHumanEsophagusESCC7.22e-091.20e+000.1276
22943DKK1P31T-EHumanEsophagusESCC1.88e-159.91e-010.1251
22943DKK1P40T-EHumanEsophagusESCC2.18e-021.18e+000.109
22943DKK1P62T-EHumanEsophagusESCC8.91e-131.58e+000.1302
22943DKK1P65T-EHumanEsophagusESCC7.37e-046.49e-010.0978
22943DKK1P75T-EHumanEsophagusESCC5.85e-773.21e+000.1125
22943DKK1HCC1_MengHumanLiverHCC2.16e-045.67e-020.0246
22943DKK1HCC2_MengHumanLiverHCC9.68e-047.19e-020.0107
22943DKK1HCC1HumanLiverHCC9.85e-155.25e+000.5336
22943DKK1S014HumanLiverHCC3.59e-724.31e+000.2254
22943DKK1S015HumanLiverHCC2.35e-725.11e+000.2375
22943DKK1S016HumanLiverHCC6.22e-874.91e+000.2243
22943DKK1C04HumanOral cavityOSCC1.96e-201.90e+000.2633
22943DKK1C21HumanOral cavityOSCC4.43e-572.92e+000.2678
22943DKK1C30HumanOral cavityOSCC2.19e-412.91e+000.3055
22943DKK1C07HumanOral cavityOSCC9.93e-032.11e+000.2491
22943DKK1C08HumanOral cavityOSCC2.14e-311.28e+000.1919
Page: 1 2 3 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:004232622LiverHCCnegative regulation of phosphorylation227/7958385/187233.98e-111.52e-09227
GO:000193322LiverHCCnegative regulation of protein phosphorylation196/7958342/187231.95e-084.63e-07196
GO:019873821LiverHCCcell-cell signaling by wnt247/7958446/187232.11e-084.96e-07247
GO:001605521LiverHCCWnt signaling pathway245/7958444/187233.68e-088.09e-07245
GO:003133312LiverHCCnegative regulation of protein-containing complex assembly91/7958141/187231.01e-071.98e-0691
GO:007099722LiverHCCneuron death202/7958361/187231.44e-072.70e-06202
GO:190121412LiverHCCregulation of neuron death179/7958319/187235.65e-079.01e-06179
GO:003011121LiverHCCregulation of Wnt signaling pathway180/7958328/187233.62e-064.72e-05180
GO:000756822LiverHCCaging185/7958339/187234.28e-065.50e-05185
GO:190121612LiverHCCpositive regulation of neuron death62/795897/187231.67e-051.81e-0462
GO:001810511LiverHCCpeptidyl-serine phosphorylation169/7958315/187233.86e-053.81e-04169
GO:004311221LiverHCCreceptor metabolic process96/7958166/187234.69e-054.50e-0496
GO:005110012LiverHCCnegative regulation of binding94/7958162/187234.69e-054.50e-0494
GO:000689821LiverHCCreceptor-mediated endocytosis134/7958244/187235.73e-055.31e-04134
GO:003209112LiverHCCnegative regulation of protein binding59/795894/187235.79e-055.34e-0459
GO:007190021LiverHCCregulation of protein serine/threonine kinase activity189/7958359/187235.97e-055.47e-04189
GO:006007021LiverHCCcanonical Wnt signaling pathway162/7958303/187237.00e-056.32e-04162
GO:003010021LiverHCCregulation of endocytosis117/7958211/187239.56e-058.32e-04117
GO:006082821LiverHCCregulation of canonical Wnt signaling pathway137/7958253/187231.15e-049.70e-04137
GO:001820911LiverHCCpeptidyl-serine modification177/7958338/187231.45e-041.17e-03177
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa05022210EsophagusESCCPathways of neurodegeneration - multiple diseases318/4205476/84656.10e-152.04e-131.05e-13318
hsa05010210EsophagusESCCAlzheimer disease263/4205384/84651.80e-145.47e-132.80e-13263
hsa0502238EsophagusESCCPathways of neurodegeneration - multiple diseases318/4205476/84656.10e-152.04e-131.05e-13318
hsa0501038EsophagusESCCAlzheimer disease263/4205384/84651.80e-145.47e-132.80e-13263
hsa0501022LiverHCCAlzheimer disease254/4020384/84653.75e-148.97e-134.99e-13254
hsa0502222LiverHCCPathways of neurodegeneration - multiple diseases298/4020476/84656.59e-121.30e-107.22e-11298
hsa0501032LiverHCCAlzheimer disease254/4020384/84653.75e-148.97e-134.99e-13254
hsa0502232LiverHCCPathways of neurodegeneration - multiple diseases298/4020476/84656.59e-121.30e-107.22e-11298
hsa0501028Oral cavityOSCCAlzheimer disease244/3704384/84651.18e-153.60e-141.83e-14244
hsa0502228Oral cavityOSCCPathways of neurodegeneration - multiple diseases292/3704476/84651.60e-154.47e-142.28e-14292
hsa05010112Oral cavityOSCCAlzheimer disease244/3704384/84651.18e-153.60e-141.83e-14244
hsa05022112Oral cavityOSCCPathways of neurodegeneration - multiple diseases292/3704476/84651.60e-154.47e-142.28e-14292
hsa0501029Oral cavityLPAlzheimer disease197/2418384/84656.66e-223.69e-202.38e-20197
hsa0502229Oral cavityLPPathways of neurodegeneration - multiple diseases232/2418476/84657.77e-223.69e-202.38e-20232
hsa0501037Oral cavityLPAlzheimer disease197/2418384/84656.66e-223.69e-202.38e-20197
hsa0502237Oral cavityLPPathways of neurodegeneration - multiple diseases232/2418476/84657.77e-223.69e-202.38e-20232
hsa0501026ProstateBPHAlzheimer disease165/1718384/84654.03e-251.66e-231.03e-23165
hsa0502226ProstateBPHPathways of neurodegeneration - multiple diseases180/1718476/84657.70e-201.81e-181.12e-18180
hsa0431014ProstateBPHWnt signaling pathway50/1718171/84653.11e-031.15e-027.14e-0350
hsa05010111ProstateBPHAlzheimer disease165/1718384/84654.03e-251.66e-231.03e-23165
Page: 1 2 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
DKK1SNVMissense_Mutationnovelc.424G>Ap.Asp142Asnp.D142NO94907protein_codingdeleterious(0.04)benign(0.026)TCGA-BH-A28O-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapycytoxanCR
DKK1SNVMissense_Mutationrs761830028c.187N>Ap.Ala63Thrp.A63TO94907protein_codingtolerated(0.38)benign(0.001)TCGA-A6-3809-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
DKK1SNVMissense_Mutationrs138915253c.358N>Tp.Arg120Cysp.R120CO94907protein_codingdeleterious(0)probably_damaging(0.999)TCGA-A6-5665-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownPD
DKK1SNVMissense_Mutationc.292N>Ap.Ala98Thrp.A98TO94907protein_codingtolerated(0.33)benign(0.15)TCGA-AA-3821-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
DKK1SNVMissense_Mutationrs145640971c.121G>Ap.Ala41Thrp.A41TO94907protein_codingdeleterious(0)benign(0.28)TCGA-AA-3947-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
DKK1SNVMissense_Mutationc.539N>Cp.His180Prop.H180PO94907protein_codingtolerated(0.3)possibly_damaging(0.731)TCGA-AA-A03F-01Colorectumcolon adenocarcinomaFemale>=65III/IVUnknownUnknownPD
DKK1SNVMissense_Mutationrs759707601c.707N>Ap.Arg236Hisp.R236HO94907protein_codingdeleterious(0)probably_damaging(0.997)TCGA-CA-6719-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownPD
DKK1SNVMissense_Mutationnovelc.632N>Cp.Lys211Thrp.K211TO94907protein_codingdeleterious(0)probably_damaging(0.997)TCGA-AG-3892-01Colorectumrectum adenocarcinomaFemale<65I/IIUnknownUnknownSD
DKK1SNVMissense_Mutationnovelc.436N>Cp.Phe146Leup.F146LO94907protein_codingtolerated(0.5)benign(0)TCGA-A5-A0G2-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
DKK1SNVMissense_Mutationc.373G>Ap.Ala125Thrp.A125TO94907protein_codingtolerated(0.08)benign(0.044)TCGA-AP-A056-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCEFLUOROURACILFLUOROURACIL25788273
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCEPROTEASOME INHIBITOR17910634
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCEDHTANDROSTANOLONE17657240
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCEPF-04840082
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCEPMID27539678-Compound-8
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCEPMID27539678-Compound-3
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCEImidamide derivative 1
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCEOXALIPLATINOXALIPLATIN25788273
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCE2-piperidine thiazole derivative 2
22943DKK1GROWTH FACTOR, DRUGGABLE GENOME, DRUG RESISTANCE2-piperidine thiazole derivative 1
Page: 1 2